Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
11 Diciembre 2023 - 8:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of December 2023
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into
English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form
40-F
CONTENTS
On December 11, 2023, Inspira
Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled “In Preparation for FDA Clearance and Device Deployment,
Inspira has Appointed Dr. Dan Gorfil to Medical Advisory Board,” a copy of which is furnished as Exhibit 99.1 with this report of
foreign private issuer on Form 6-K.
The
Report on Form 6-K is incorporated by reference into the Registrant’s Registration Statements
on Form F-3 (Registration No. 333-266748) and Form S-8 (Registration No. 333-259057), filed with the Securities and
Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
Inspira Technologies Oxy B.H.N. Ltd. |
|
|
|
Date: December 11, 2023 |
By: |
/s/ Dagi Ben-Noon |
|
|
Name: |
Dagi Ben-Noon |
|
|
Title: |
Chief Executive Officer |
2
Exhibit 99.1
In Preparation for FDA Clearance and Device
Deployment, Inspira has Appointed Dr. Dan Gorfil to Medical Advisory Board
Ra’anana, Israel, December 11, 2023 –
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), a pioneer in life
support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil
to its medical advisory board.
Dr. Gorfil
is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery
Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center,
Israel. Dr. Gorfil’s expertise is expected to significantly contribute to the deployment of the INSPIRA™ ART100. U.S. Food
and Drug Administration (FDA) approval is expected in the first half of 2024.
“My
commitment to life support innovation led me to Inspira Technologies,” stated Dr. Gorfil. “I believe that the Company’s
innovative technology will revolutionize critical care treatment. I am thrilled to be a part of this transformative journey.”
Dagi Ben-Noon, CEO of Inspira
Technologies, commented, “Dr. Gorfil’s appointment represents a strategic step towards accelerating our technology’s
time-to-market. I believe that his deep expertise and extensive network within the life support sector are valuable to both patients and
our investors.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is leading the way in transforming
life-support care. Its innovative solutions are paving the way for direct blood oxygenation, bypassing the lungs, and potentially reducing
the need for traditional mechanical ventilation. Beyond this, the Company is committed to advancing blood circulation technology and incorporating
AI-driven monitoring systems. These advancements are part of its strategy to offer more patient-focused, data-informed care. The integration
of these technologies signifies the potential to enhance patient outcomes and streamline hospital operations, marking a new era in respiratory
care.
For more information, please visit our corporate website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied
forward-looking statements under U.S. Federal securities laws. These forward-looking statements and their implications are based only
on the current expectations of the management of the Company. They are subject to several factors and uncertainties that could cause results
to differ materially from those described in the forward-looking statements. For example, the Company uses forward-looking statements
when it discusses the Company’s vision to supersede traditional mechanical ventilators, that the Company expects Dr Gorfil’s
expertise to significantly contribute to the deployment of the INSPIRA Art 1000, that FDA approval for the INSPIRA Art 1000 is expected
in the first half of 2024, that Dr. Gorfil believes that the Company’s innovative technology will revolutionize critical care treatment,
and that the Company believes that Dr. Gorfil’s appointment represents a strategic step towards accelerating the Company’s
technology’s time-to-market. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after the date hereof or the occurrence of unanticipated events.
More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors”
in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2022, filed with the SEC, which is available
on the SEC’s website, www.sec.gov.
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2023 Inspira Technologies
OXY B.H.N. LTD., All rights reserved.
MRK-ARS-076
Inspira Technologies Oxy... (NASDAQ:IINN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Inspira Technologies Oxy... (NASDAQ:IINN)
Gráfica de Acción Histórica
De May 2023 a May 2024